Synthesis, characterization and in vitro studies of pegylated melphalan conjugates

References

• Niranjan NP, John HM, John HP. (1996). Synthesis of Co-Drugs of Alkylating Agents and Steroidal Anti-Inflammatories. Drug Dev Ind Pharm, 22:181–184.
   Web of Science ®Google Scholar
• Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. (1988). The systemic administration of intravenous melphalan. J Clin Oncol, 6:1768–1782.
   PubMed Web of Science ®Google Scholar
• Samuels BL, Bitran JD. (1995). High-dose intravenous melphalan: a review. J Clin Oncol, 13:1786–1799.
   PubMed Web of Science ®Google Scholar
• Jonkman-De Vries JD, Flora KP, Bult A, Beijnen JH. (1996). Pharmaceutical Development of (Investigational) Anticancer Agents for Parenteral Use-A Review. Drug Dev Ind Pharm, 22:475–494.
   Web of Science ®Google Scholar
• David Attivi, Imane Ajana, Alain Astier, Béatrice Demoré, Stéphane Gibaud. (2010). Development of microemulsion of mitotane for improvement of oral bioavailability. Drug Dev Ind Pharm, 36:421–427.
   PubMed Web of Science ®Google Scholar
• Geerligs IEJ, Beijnen JH, Bekers O, Underberg WJM. (1993). Quality Control of Protein and Peptide Drugs: Monoclonal Antibodies and some Biological Response Modifiers Derived by Recombinant DNA Technology. Drug Dev Ind Pharm, 19:33–84.
   Web of Science ®Google Scholar
• Tracy Chen. (1992). Formulation concerns of protein drugs. Drug Dev Ind Pharm, 18:1311–1354.
   Web of Science ®Google Scholar
• Lockman PR, Mumper RJ, Khan MA, Allen DD. (2002). Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm, 28:1–13.
   PubMed Web of Science ®Google Scholar
• Choi KE, Ratain MJ, Williams SF, Golick JA, Beschorner JC, Fullem LJ et al. (1989). Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion. Cancer Res, 49:1318–1321.
   PubMed Web of Science ®Google Scholar
• Cuilian Peng, Cong Liu, Xing Tang. (2010). Determination of physicochemical properties and degradation kinetics of triamcinolone acetonide palmitate in vitro. Drug Dev Ind Pharm, 36:1469–1476.
   PubMed Web of Science ®Google Scholar
• Kalle Sigfridsson, Anders Lundqvist, Marie Strimfors. (2011). Co-administration of a nanosuspension of a poorly soluble basic compound and a solution of a proton pump inhibitor—the importance of gastrointestinal pH and solubility for the in vivo exposure. Drug Dev Ind Pharm, 37:1036–1042.
   PubMed Web of Science ®Google Scholar
• Katharina Leithner, Vjera Grabovac, Karin Albrecht, Juliane Hombach, Günter Klima. (2011). Andreas Bernkop-Schnürch.Permeation studies on freshly excised rat gastric mucosa: influence of pH. Drug Dev Ind Pharm, 37:518–525.
   PubMed Web of Science ®Google Scholar
• Yue-Hua Liu, Xi Zhu, Dan Zhou, Yun Jin, Chun-Yan Zhao, Zhi-Rong Zhang, Yuan Huang. (2011). pH-Sensitive and mucoadhesive microspheres for duodenum-specific drug delivery system. Drug Dev Ind Pharm, 37:868–874.
   PubMed Web of Science ®Google Scholar
• Evans TL, Chang SY, Alberts DS, Sipes IG, Brendel K. (1982). In vitro degradation of L-phenylalanine mustard (L-PAM). Cancer Chemother Pharmacol, 8:175–178.
   PubMed Web of Science ®Google Scholar
• Tegafur José L. Arias, Margarita López-Viota, Visitación Gallardo, María Adolfina Ruiz. (2010). Chitosan nanoparticles as a new delivery system for the chemotherapy agent. Drug Dev Ind Pharm, 36:744–750.
   PubMed Web of Science ®Google Scholar
• Shimon Ben-Shabat, Nir Baruch, Amnon C. Sintov. (2007). Conjugates of Unsaturated Fatty Acids with Propylene Glycol as Potentially Less-Irritant Skin Penetration Enhancers. Drug Dev Ind Pharm, 33:1169–1175.
   PubMed Web of Science ®Google Scholar
• Yoncheva K, Doytchinova I, Irache JM. (2010). Different approaches for determination of the attachment degree of polyethylene glycols to poly(anhydride) nanoparticles. Drug Dev Ind Pharm, 36:676–680.
   PubMed Web of Science ®Google Scholar
• Ajazuddin, Saraf S. (2010). Applications of novel drug delivery system for herbal formulations. Fitoterapia, 81:680–689.
   PubMed Web of Science ®Google Scholar
• Enam Khalil, Najjar S, Sallam A. (2000). Aqueous Solubility of Diclofenac Diethylamine in the Presence of Pharmaceutical Additives: A Comparative Study with Diclofenac Sodium. Drug Dev Ind Pharm 26:375–381.
   PubMed Web of Science ®Google Scholar
• Andrei Dashevsky, Abid Riaz Ahmed, Mota J, Muhammad Irfan, Karl Kolter, Roland A Bodmeier. (2010). Effect of water-soluble polymers on the physical stability of aqueous polymeric dispersions and their implications on the drug release from coated pellets. Drug Dev Ind Pharm, 36:152–160.
   PubMed Web of Science ®Google Scholar
• Hooftman G, Herman S, Schacht E. (1996). Poly (Ethylene Glycol)s with Reactive Endgroups. II Practical Consideration for the Preparation of Protein-PEG Conjugates. J Bioact Compat Polymers, 11:135–159.
   Web of Science ®Google Scholar
• Lu ZR, Kopecková P, Wu Z, Kopecek J. (1998). Functionalized semitelechelic poly[N-(2-hydroxypropyl)methacrylamide] for protein modification. Bioconjug Chem, 9:793–804.
   PubMed Web of Science ®Google Scholar
• Russ Middaugh. (2008). A Review of: Vaccine Adjuvants and Delivery Systems. Drug Dev Ind Pharm, 34:347–347.
   Google Scholar
• Richter AW, Akerblom E. (1983). Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol, 70:124–131.
   PubMedGoogle Scholar
• Vandegriff KD, McCarthy M, Rohlfs RJ, Winslow RM. (1997). Colloid osmotic properties of modified hemoglobins: chemically cross-linked versus polyethylene glycol surface-conjugated. Biophys Chem, 69:23–30.
   PubMed Web of Science ®Google Scholar
• Abuchowski A, van Es T, Palczuk NC, Davis FF. (1977). Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem, 252:3578–3581.
   PubMed Web of Science ®Google Scholar
• Working PK, Newman MS, Johnson J, Harris JM, Zalipsky S. (1997). Poly (ethylene glycol) Chemistry and Biological applications. ACS Books: Washington DC ; 45–57.
   Google Scholar
• Kurtzberg J, Holland JF, Bast RC, Morton DL, Frei E, Kufe JW, Weichselbaum RR. (1997). Cancer medicine: 4th edition, Baltimore, MD, Lippincott Williams and Wilkins 1027–1036.
   Google Scholar
• Wang YS, Youngster S, Bausch J, Zhang R, McNemar C, Wyss DF. (2000). Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry, 39:10634–10640.
   PubMed Web of Science ®Google Scholar
• Yousefi G, Foroutan SM, Zarghi A, Shafaati A. (2010). Synthesis and characterization of methotrexate polyethylene glycol esters as a drug delivery system. Chem Pharm Bull, 58:147–153.
   PubMed Web of Science ®Google Scholar
• Jasmin K, Martina M, Juergen S, Peter LT, Hans PS, Günter A. (2010). GEMMA and MALDI-TOF MS of reactive PEGs for pharmaceutical applications. J Pharm Biomed Anal, 52:432–437.
   PubMed Web of Science ®Google Scholar
• Vandermeulen G, Rouxhet L, Arien A, Brewster ME, Préat V. (2006). Encapsulation of amphotericin B in poly(ethylene glycol)-block-poly(epsilon-caprolactone-co-trimethylenecarbonate) polymeric micelles. Int J Pharm, 309:234–240.
   PubMed Web of Science ®Google Scholar
• Williams R O III. (2006). A Review of: “Pharmaceutical Dissolution Testing”. Drug Dev Ind Pharm, 32:401–401.
   Google Scholar
• Williams R O, III. (2006). A Review of: “HPCL Methods for Recently Approved Pharmaceuticals”. Drug Dev Ind Pharm, 32:907–907.
   Google Scholar
• Wang X, Tian Y, Hansen L, Zang L. (2010). Preparation and characterization of PEGylatedterlipressin. J Appl Poly Sci, 116:3220–3224.
   Web of Science ®Google Scholar
• Conover CD, Pendri A, Lee C, Gilbert CW, Shum KL, Greenwald RB. (1997). Camptothecin delivery systems: the antitumor activity of a camptothecin-20-0-polyethylene glycol ester transport form. Anticancer Res, 17:3361–3368.
   PubMed Web of Science ®Google Scholar
• Conover CD, Greenwald RB, Pendri A, Gilbert CW, Shum KL. (1998). Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother Pharmacol, 42:407–414.
   PubMed Web of Science ®Google Scholar
• Greenwald RB, Pendri A, Bolikal D, Gilbert CW. (1994). Highly water soluble taxol derivatives: 2-polyethyleneglycol estersas potential prodrugs. Bioorg Med ChemLett, 4:2465–2470.
   Web of Science ®Google Scholar
• Greenwald RB, Choe YH, McGuire J, Conover CD. (2003). Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev, 55:217–250.
   PubMed Web of Science ®Google Scholar
• Monfardini C, Schiavon O, Caliceti P, Morpurgo M, Harris JM, Veronese FM. (1995). A branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug Chem, 6:62–69.
   PubMed Web of Science ®Google Scholar
• Lavasanifar A, Samuel J, Kwon GS. (2002). The effect of fatty acid substitution on the in vitro release of amphotericin B from micelles composed of poly(ethylene oxide)-block-poly(N-hexyl stearate-L-aspartamide). J Control Release, 79:165–172.
   PubMed Web of Science ®Google Scholar
• Neta P, Mika R, Marina S, Ferda Y, Hong X, Katherine NS, Gil A, Doron S. (2004). Bioactivation of carbamate-based 20(S)-camptothecinprodrugs. Bioorg Med Chem, 12:185–186.
   Google Scholar
• Hugh DC Smyth. (2006). A Review of: “Polymeric Drug Delivery Systems”. Drug Dev Ind Pharm, 32:1111–1111.
   Google Scholar